IGHMBP2 and Parkinson disease: On the other hand, null-treated animals presented a downregulation of genes involved in lipid metabolism vs WT (e.g. Cyp1a2, Serpina6, Fabp1, Fitm1, Prkag3, Bglap, Alox12), confirming the potential involvement of energetic metabolism impairments in SMARD1, similar to what is already suggested in other neurodegenerative diseases such as Alzheimer and Parkinson Diseases, ALS and Huntington's Disease [38].